title: "Zika Virus: Is Europe at Risk in 2026?" date: "2026-04-03" excerpt: "Zika virus poses a growing risk to Europe as tiger mosquitoes expand. Learn about microcephaly risks, sexual transmission, and travel advice for pregnant women." category: "diseases" author: "Mosticare Editorial"

Zika Virus: Is Europe at Risk?

By Mosticare Editorial | Published 2026-04-03

The Zika virus pandemic of 2015-2016 horrified the world with images of newborns suffering from microcephaly -- an abnormally small head caused by impaired brain development during pregnancy. The epidemic was concentrated in the Americas, particularly Brazil, and Europe watched from a safe distance. But that distance is shrinking.

With Aedes albopictus now established in 369 regions across 16 EU/EEA countries, the mosquito capable of transmitting Zika is already deeply embedded in European territory. The question is no longer whether the vector is present, but whether the virus will follow.

What Is Zika Virus?

Zika virus (ZIKV) is a flavivirus first identified in Uganda's Zika Forest in 1947. For decades it caused only sporadic human infections in Africa and Asia. That changed dramatically in 2013-2014 when it reached the Pacific Islands and then Latin America, triggering a public health emergency of international concern declared by the WHO.

Transmission Routes

Zika is primarily transmitted through the bite of infected Aedes mosquitoes -- both Aedes aegypti (the primary global vector) and Aedes albopictus (the species present in Europe). However, Zika has additional transmission routes that make it unique among mosquito-borne diseases:

Sexual transmission: Zika can be passed from an infected person to their partner through sexual contact. The virus can persist in semen for weeks to months after infection.
Vertical transmission: An infected pregnant woman can pass the virus to her foetus, potentially causing congenital Zika syndrome.
Blood transfusion: Documented cases of transfusion-transmitted Zika have been reported.

The Microcephaly Connection

The defining feature of Zika's public health impact is its effect on pregnancy. Infection during pregnancy -- particularly in the first and second trimesters -- can cause congenital Zika syndrome, which includes:

Microcephaly: Severely reduced head circumference due to incomplete brain development
Brain abnormalities: Including calcifications, ventriculomegaly, and cortical malformations
Eye defects: Scarring of the retina and other ocular abnormalities
Joint contractures: Restricted limb movement (arthrogryposis)
Neurological impairment: Seizures, developmental delays, and feeding difficulties

During the 2015-2016 epidemic, Brazil reported more than 2,600 confirmed cases of microcephaly linked to Zika infection. The emotional and economic burden on affected families is immense and lifelong.

Symptoms in Non-Pregnant Adults

For most adults, Zika infection is mild or entirely asymptomatic. According to the ECDC, approximately 80 percent of infections produce no symptoms. When symptoms do occur, they typically include:

Low-grade fever
Maculopapular rash (flat red spots)
Joint pain (usually mild, unlike chikungunya)
Conjunctivitis (red eyes)
Muscle pain and headache
Fatigue

Symptoms usually resolve within 2 to 7 days. However, Zika has been associated with Guillain-Barre syndrome, a rare autoimmune condition that attacks the nervous system and can cause temporary paralysis.

Europe's Current Risk Level

The WHO Regional Office for Europe has assessed the overall risk of Zika to Europe as low to moderate. No sustained local transmission has been documented on the European mainland. However, several factors keep the threat alive:

The Vector Is Already Here

Aedes albopictus has been demonstrated as a competent vector for Zika virus in laboratory settings and is now present across Mediterranean Europe. As the MDPI research journal documented, all three major Aedes-borne viruses (dengue, chikungunya, and Zika) are increasingly relevant threats to Europe's epidemiological landscape.

Viraemic Travellers

With Zika resurgent in parts of South America -- particularly Brazil in 2025 -- the risk of infected travellers arriving in Europe and being bitten by local mosquitoes remains real. France reported four travel-related Zika cases in August 2025.

Climate Trends Favour Expansion

The same warming temperatures and extended mosquito seasons driving dengue and chikungunya outbreaks in Europe also create conditions conducive to Zika transmission. As the tiger mosquito pushes further north and the season lengthens, the geographic window for potential Zika transmission widens.

No Vaccine Available

There is currently no approved Zika vaccine. Several candidates have been in development since the 2016 epidemic, but none have achieved regulatory approval. This leaves prevention as the sole tool.

Travel Advice for Pregnant Women

Given the severity of congenital Zika syndrome, pregnant women and those planning pregnancy should take particular precautions:

Check travel advisories: Before travelling to any region with known or suspected Zika transmission, consult the CDC's country-specific risk information and your national health authority.
Prevent mosquito bites rigorously: In areas with Aedes albopictus populations (most of southern Europe during summer), use physical barriers, protective clothing, and approved repellents.
Be aware of sexual transmission: If your partner has travelled to a Zika-endemic area, barrier contraception should be used for at least three months after the trip, per WHO guidance.
Consult your healthcare provider: If you develop symptoms consistent with Zika during pregnancy, seek medical attention promptly. Testing is available through national reference laboratories.

Protection Strategies

For Everyone in Tiger Mosquito Areas

Eliminate standing water around homes and workplaces
Install fine-mesh window and door screens
Use physical mosquito barriers for outdoor activities during daylight hours
Wear long, light-coloured clothing during peak biting times (morning and late afternoon)

For Communities

Support municipal mosquito surveillance and control programmes
Report tiger mosquito sightings to local health authorities
Advocate for proactive vector management in your neighbourhood

For Healthcare Providers

Consider Zika in the differential diagnosis for patients presenting with rash, conjunctivitis, and joint pain, particularly those with recent travel to endemic regions or those living in areas with established Aedes albopictus populations during transmission season.

Frequently Asked Questions

Has Zika virus been transmitted locally in Europe?

As of early 2026, no sustained local Zika transmission has been confirmed on the European mainland. However, the vector (Aedes albopictus) is established across 16 EU countries, and the risk of introduction through viraemic travellers exists.

Can men transmit Zika through sexual contact?

Yes. Zika virus can persist in semen for weeks to months. The WHO recommends barrier contraception for at least three months after potential exposure.

Is there a Zika vaccine?

No. Despite multiple candidates in development since 2016, no Zika vaccine has been approved for human use.

About Mosticare: Mosticare develops chemical-free mosquito protection solutions for homes, businesses, and communities across Europe. Our mission: a green, mosquito-free life for every European. Learn more

Sources cited in this article: